These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36239337)

  • 1. Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer.
    Choi SH; Do SK; Lee SY; Choi JE; Kang HG; Hong MJ; Lee JH; Lee WK; Jeong JY; Shin KM; Do YW; Lee EB; Park JE; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2022 Dec; 13(23):3322-3330. PubMed ID: 36239337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
    Choi SH; Jin CC; Do SK; Lee SY; Choi JE; Kang HG; Kim JH; Lee JH; Hong MJ; Lee WK; Jeong JY; Shin KM; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Oncology; 2020; 98(7):468-477. PubMed ID: 32252059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet.
    Ryu JS; Lim JH; Kim HJ; Kim MJ; Park MH; Kim JS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
    Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
    Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
    Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid.
    Li X; Tang X; Su J; Xu G; Zhao L; Qi Q
    Biochem Pharmacol; 2019 Nov; 169():113635. PubMed ID: 31513784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
    PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.
    Lee SJ; Kang BW; Chae YS; Kim HJ; Park SY; Park JS; Choi GS; Jeon HS; Lee WK; Kim JG
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S634-9. PubMed ID: 24770722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
    Han D; Li SJ; Zhu YT; Liu L; Li MX
    Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
    Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective.
    Ciccarese F; Zulato E; Indraccolo S
    Oxid Med Cell Longev; 2019; 2019():8730816. PubMed ID: 31781355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
    Liu JL; Mao Z; Gallick GE; Yung WK
    Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.